OncoCyte Corporation (OCX)

OncoCyte Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	7.28	11.13	21.69	34.65	8.84	22.07
Short-Term Investments	0	0	0.43	0.9	0.68	0.38
Cash & Cash Equivalents	7.28	11.13	22.13	35.55	9.52	22.45
Cash Growth	-48.22%	-49.69%	-37.76%	273.52%	-57.61%	165.32%
Receivables	0.16	0.48	2.01	1.44	0.2	0
Other Current Assets	-0.9	-0.92	1.4	2.15	-0.5	0.51
Total Current Assets	6.54	10.7	25.54	39.14	9.23	22.96
Property, Plant & Equipment	5.73	5.44	10.85	8.37	6.52	3.73
Long-Term Investments	0	0	0	0	13.42	10.96
Goodwill and Intangibles	56.57	56.6	61.63	80.41	24.2	0
Other Long-Term Assets	2.14	2.16	2.07	31.65	2.06	2.21
Total Long-Term Assets	64.44	64.19	74.56	120.42	46.19	16.9
Total Assets	70.97	74.89	100.09	159.56	55.42	39.86
Accounts Payable	0.91	0.95	1.25	1.81	0.43	0.48
Current Debt	0.82	0.67	0.82	2.13	2.81	1.36
Other Current Liabilities	6.6	5.58	10.04	10.18	5.75	2.61
Total Current Liabilities	8.33	7.19	12.11	14.12	9	4.44
Long-Term Debt	2.51	2.2	2.73	3.55	5.82	4.58
Other Long-Term Liabilities	43.21	39.9	45.66	76.68	7.12	0
Total Long-Term Liabilities	45.73	42.1	48.39	80.23	12.94	4.58
Total Liabilities	54.05	49.3	60.5	94.35	21.94	9.02
Total Debt	3.34	2.87	3.54	5.68	8.63	5.94
Debt Growth	0.30%	-19.05%	-37.57%	-34.23%	45.42%	245.32%
Retained Earnings	-299.01	-289.88	-260.68	-187.77	-123.68	-93.75
Comprehensive Income	0.04	0.05	0.04	0.04	0	0
Shareholders' Equity	11.59	20.47	34.29	65.22	33.48	30.84
Net Cash / Debt	3.94	8.26	18.58	29.88	0.89	16.52
Net Cash / Debt Growth	-63.26%	-55.53%	-37.80%	3271.90%	-94.64%	144.92%
Net Cash Per Share	0.48	1.08	3.35	6.72	0.27	6.44
Working Capital	-1.79	3.5	13.43	25.02	0.23	18.52
Book Value Per Share	1.40	2.67	6.19	14.67	10.23	12.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).